Duration of Targeted Therapy in Patients With Advanced Non-small-cell Lung Cancer Identified by Circulating Tumor DNA Analysis
Copyright © 2020. Published by Elsevier Inc..
BACKGROUND: Outcomes of therapy targeting molecular driver alterations detected in advanced non-small-cell lung (NSCLC) using circulating tumor DNA (ctDNA) have not been widely reported in patients who are targeted therapy-naive.
PATIENTS AND METHODS: We performed a multicenter retrospective review of patients with unresectable stage IIIB to IV NSCLC who received matched therapy after a targetable driver alteration was identified using a commercial ctDNA assay through usual clinical care. Eligible patients must not have received targeted therapy prior to ctDNA testing (prior chemotherapy or immunotherapy was permitted). Kaplan-Meier analysis was used to estimate the median duration of targeted therapy. Patients still on targeted therapy were censored at last follow-up.
RESULTS: Seventy-six patients met inclusion criteria. The median age of diagnosis of NSCLC was 64.5 years (range, 31-87 years), 67% were female, 74% were never-smokers, and 97% had adenocarcinoma histology. Twenty-one (28%) patients received systemic treatment prior to targeted therapy, including chemotherapy (n = 17), immunotherapy (n = 5), and/or a biologic (n = 4). Thirty-three (43%) patients remain on targeted therapy at the time of data analysis. The median time on targeted therapy was similar to what has been reported for tissue-detected oncogenic driver mutations in the targeted therapy-naive setting.
CONCLUSIONS: Patients with ctDNA-detected drivers had durable time on targeted therapy. These treatment outcomes data compliment previous studies that have shown enhanced targetable biomarker discovery rates and high tissue concordance of ctDNA testing when incorporated at initial diagnosis of NSCLC. Identification of NSCLC driver mutations using well-validated ctDNA assays can be used for clinical decision-making and targeted therapy assignment.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
---|---|
Enthalten in: |
Clinical lung cancer - 21(2020), 6 vom: 03. Nov., Seite 545-552.e1 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Reckamp, Karen L [VerfasserIn] |
---|
Links: |
---|
Themen: |
Biomarkers, Tumor |
---|
Anmerkungen: |
Date Completed 11.10.2021 Date Revised 16.07.2022 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1016/j.cllc.2020.06.015 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM312417039 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM312417039 | ||
003 | DE-627 | ||
005 | 20231225144355.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.cllc.2020.06.015 |2 doi | |
028 | 5 | 2 | |a pubmed24n1041.xml |
035 | |a (DE-627)NLM312417039 | ||
035 | |a (NLM)32665165 | ||
035 | |a (PII)S1525-7304(20)30209-6 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Reckamp, Karen L |e verfasserin |4 aut | |
245 | 1 | 0 | |a Duration of Targeted Therapy in Patients With Advanced Non-small-cell Lung Cancer Identified by Circulating Tumor DNA Analysis |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 11.10.2021 | ||
500 | |a Date Revised 16.07.2022 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright © 2020. Published by Elsevier Inc. | ||
520 | |a BACKGROUND: Outcomes of therapy targeting molecular driver alterations detected in advanced non-small-cell lung (NSCLC) using circulating tumor DNA (ctDNA) have not been widely reported in patients who are targeted therapy-naive | ||
520 | |a PATIENTS AND METHODS: We performed a multicenter retrospective review of patients with unresectable stage IIIB to IV NSCLC who received matched therapy after a targetable driver alteration was identified using a commercial ctDNA assay through usual clinical care. Eligible patients must not have received targeted therapy prior to ctDNA testing (prior chemotherapy or immunotherapy was permitted). Kaplan-Meier analysis was used to estimate the median duration of targeted therapy. Patients still on targeted therapy were censored at last follow-up | ||
520 | |a RESULTS: Seventy-six patients met inclusion criteria. The median age of diagnosis of NSCLC was 64.5 years (range, 31-87 years), 67% were female, 74% were never-smokers, and 97% had adenocarcinoma histology. Twenty-one (28%) patients received systemic treatment prior to targeted therapy, including chemotherapy (n = 17), immunotherapy (n = 5), and/or a biologic (n = 4). Thirty-three (43%) patients remain on targeted therapy at the time of data analysis. The median time on targeted therapy was similar to what has been reported for tissue-detected oncogenic driver mutations in the targeted therapy-naive setting | ||
520 | |a CONCLUSIONS: Patients with ctDNA-detected drivers had durable time on targeted therapy. These treatment outcomes data compliment previous studies that have shown enhanced targetable biomarker discovery rates and high tissue concordance of ctDNA testing when incorporated at initial diagnosis of NSCLC. Identification of NSCLC driver mutations using well-validated ctDNA assays can be used for clinical decision-making and targeted therapy assignment | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Multicenter Study | |
650 | 4 | |a Research Support, N.I.H., Extramural | |
650 | 4 | |a Genotype directed therapy | |
650 | 4 | |a Liquid biopsy | |
650 | 4 | |a Lung cancer | |
650 | 4 | |a Oncogene | |
650 | 7 | |a Biomarkers, Tumor |2 NLM | |
650 | 7 | |a Circulating Tumor DNA |2 NLM | |
700 | 1 | |a Patil, Tejas |e verfasserin |4 aut | |
700 | 1 | |a Kirtane, Kedar |e verfasserin |4 aut | |
700 | 1 | |a Rich, Thereasa A |e verfasserin |4 aut | |
700 | 1 | |a Espenschied, Carin R |e verfasserin |4 aut | |
700 | 1 | |a Weipert, Caroline M |e verfasserin |4 aut | |
700 | 1 | |a Raymond, Victoria M |e verfasserin |4 aut | |
700 | 1 | |a Santana-Davila, Rafael |e verfasserin |4 aut | |
700 | 1 | |a Doebele, Robert C |e verfasserin |4 aut | |
700 | 1 | |a Baik, Christina S |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Clinical lung cancer |d 1999 |g 21(2020), 6 vom: 03. Nov., Seite 545-552.e1 |w (DE-627)NLM143155229 |x 1938-0690 |7 nnns |
773 | 1 | 8 | |g volume:21 |g year:2020 |g number:6 |g day:03 |g month:11 |g pages:545-552.e1 |
856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.cllc.2020.06.015 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 21 |j 2020 |e 6 |b 03 |c 11 |h 545-552.e1 |